ClinicalTrials.gg
RecruitingNCT06664359Updated Oct 29, 2024

Safe Zone in Trigger Point Injection

An observational study in Trigger Point Pain, Myofascial, sponsored by Ankara University. Recruiting at 1 site in Turkey. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-10-29.

Sponsored by Ankara University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
211
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Myofascial Pain Syndromes with a site in Turkey — 12 open to participants now, 12 under way, none of them phase 3. Myofascial Pain Syndromes · Turkey.

Planned enrollment
Largest of 14
211 · median 110
Started
2024
with 8 others
Observational
14 of 81
2 open now
Primary completion
2024-12
later than 1 of 11 live
Registered
56th of 81
by date
Lead sponsor
5 of 81
Ankara University

Among the 81 studies in Myofascial Pain Syndromes with a site in Turkey, this one has the largest planned enrollment of the 14 observational ones that give a count, is one of 9 that started in 2024, is one of 14 observational ones, reaches primary completion later than 1 of the 11 other live ones, and was the 56th registered.

Myofascial Pain Syndromes

340 studies on the registry are indexed under Myofascial Pain Syndromes; 67 are open to participants now.

Browse Myofascial Pain Syndromes studies →

Open to participants now

12 of the 81 studies in Myofascial Pain Syndromes with a site in Turkey are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 35 Myofascial Pain Syndromes studies recruiting now, 6 (17%) set no upper age limit and 26 (74%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Myofascial Pain Syndromes with a site in Turkey, or all of them as a file.
02

Study summary

The goal of this observational study is to define the safe distance that will reduce the risk of pneumothorax through ultrasonographic imaging measurements in both sitting and prone positions to ensure patient safety during these procedures. The main question[s] it aims to answer [is/are]:

The mean distance between the skin and pleura in sitting position during the inhalation and exhalation The mean distance between the skin and pleura in prone position during the inhalation and exhalation

Read the detailed description

Myofascial pain syndrome is characterized by pain and tenderness at specific points known as trigger points. Tension and spasm occur in the muscles, making it one of the most common causes of musculoskeletal pain. Various treatment options, such as TENS, dry needling, and trigger point injections, are available for the management of myofascial pain syndrome. Trigger point injection is one of the evidence based treatment methods that can provide both temporary and long-term relief.

Trigger point injections can be performed under ultrasound guidance or by blind technique. Although trigger point injection is generally be considered a safe procedure when performed by a skilled practitioner, complications may occur. These complications include pain during and after the procedure, nerve injury, bleeding, infection, and serious complications such as pneumothorax. Pneumothorax may occur when trigger point injections are administered into the chest wall muscles, particularly the trapezius, rhomboid major, or rhomboid minor muscles. Among these muscles, the rhomboid major is very thin, and the thickness of the skin, subcutaneous fat layer, and other soft tissues surrounding it varies between individuals. Since nerves, vascular structures, and the pleura are present in the deeper parts of these muscles, determining the appropriate injection depth is crucial.

In clinical practice, trigger point injections are administered by clinicians in both prone and sitting positions. To the best of our knowledge there is no studies thatinvestigates the determination of a safe distance through measurements in both the sitting and prone positions. In this study we aim to calculate the safe distance using ultrasound that will reduce the risk of pneumothorax through ultrasonographic imaging measurements in both sitting and prone positions during inhalation and exhalation to ensure patient safety during these procedures.

03

Conditions studied

  • Trigger Point Pain, Myofascial

Keywords

  • Trigger Point Pain
  • Myofascial pain
  • ultrasound
  • pneumothorax
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients scheduled to undergo trigger point injections due to myofascial pain

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients diagnosed with Myofascial Pain Syndrome
  • patients scheduled for trigger point injections due to Myofascial Pain Syndrome.

Exclusion criteria

Exclusion Criteria:

  • under 18 years of age,
  • additional diseases other than Myofascial Pain Syndrome,
  • the presence of active infection in the interscapular area where ultrasound imaging and measurements will be performed,
  • lesions that disrupt skin integrity or affect subcutaneous and muscle structures such as anomalies or masses that could impair imaging quality
  • individuals with known lung diseases
  • not consent to participate in the study."
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
211 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • myofascial pain

    myofascial pain syndrome

    Other: Ultrasound guided injection with local anaestethic

Interventions

  • OtherUltrasound guided injection with local anaestethic

    Volunteers will first be asked to sit on a chair with their back facing the examiner, placing their arms in a relaxed position with their head supported on a surface in front of them. The ultrasound operator will be positioned behind the volunteer. Initially, in the sitting position, volunteers will be asked to maintain normal breathing. Once an optimal ultrasound image is obtained, the image will be frozen, and measurements will be taken from the same image in sequence. The measurements to be performed are as follows: skin-fat tissue distance, skin-trapezius muscle distance, skin-rhomboid muscle distance, skin-rib distance, skin-pleura distance, and rhomboid muscle-pleura distance. These measurements, in millimeters, will be recorded in the data collection form. The same measurements will also be taken during deep inhalation and deep exhalation in the sitting position."

  • OtherUltrasound guided injection with local anaestethic

    Volunteers will first be asked to lay prone position.The ultrasound operator will be positioned behind the volunteer. Initially, in the sitting position, volunteers will be asked to maintain normal breathing. Once an optimal ultrasound image is obtained, the image will be frozen, and measurements will be taken from the same image in sequence. The measurements to be performed are as follows: skin-fat tissue distance, skin-trapezius muscle distance, skin-rhomboid muscle distance, skin-rib distance, skin-pleura distance, and rhomboid muscle-pleura distance. These measurements, in millimeters, will be recorded in the data collection form. The same measurements will also be taken during deep inhalation and deep exhalation in the sitting position."

06

What researchers measure

Primary outcomes

  1. skin-pleura distance in sitting position

    Evaluate the skin-pleura distance in sitting position during inhalation and exhalation

    Time frame: 1 day

  2. skin-pleura distance in prone position

    skin-pleura distance in prone position during inhalation and exhalation

    Time frame: 1 day

Secondary outcomes

  1. the correlation of skin-pleura distance and body mass index

    the correlation of skin-pleura distance in sitting and prone position and body mass index

    Time frame: 1 day

  2. the correlation of skin-pleura distance and dominant hand

    the correlation of skin-pleura distance in sitting and prone position and dominant hand

    Time frame: 1 day

  3. the correlation of skin-pleura distance and the chest wall diameter

    the correlation of skin-pleura distance in sitting and prone position and the chest wall diameter

    Time frame: 1 day

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Mitchell UH, Johnson AW, Larson RE, Seamons CT. Positional changes in distance to the pleura and in muscle thickness for dry needling. Physiotherapy. 2019 Sep;105(3):362-369. doi: 10.1016/j.physio.2018.08.002. Epub 2018 Aug 18. PubMed 30343872 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for Dec 2024, 2 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2024
First posted
Oct 29, 2024
StartActual
Oct 1, 2024
Primary completionEst.
Dec 30, 2024
CompletionEst.
Dec 30, 2024
Last update
Oct 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06664359
Lead sponsor
Ankara University
Responsible party
Süheyla Karadağ Erkoç (Medical Doctor, Ankara University) — Principal investigator
First posted
Oct 29, 2024
Start date
Oct 1, 2024
Primary completion
Dec 30, 2024 (estimated)
Completion
Dec 30, 2024 (estimated)
Last update
Oct 29, 2024

Study contacts

Süheyla Karadağ Erkoç, MD
Contact
suheylakaradag@hotmail.com
+905063994839 ext. +905063994839
Büşra Şahin Kıdam, MD
Contact
kidambusra@hotmail.com
+905448387763 ext. +905448387763
Suheyla Karadağ-Erkoç, MD
study director · Department of Anesthesiology and Reanimation, Ankara University, Ankara, Turkey

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion